In today’s session Ophthotech Corp (OPHT) registered an unusually high (401) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious OPHT increase. With 401 contracts traded and 45124 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: OPHT170120C00040000 closed last at: $14.9 or 16.4% up. About 458,941 shares traded hands. Ophthotech Corp (NASDAQ:OPHT) has declined 32.48% since April 7, 2016 and is downtrending. It has underperformed by 37.26% the S&P500.
Ophthotech Corp (NASDAQ:OPHT) Ratings Coverage
Out of 10 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 9 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 90% are positive. $200 is the highest target while $45 is the lowest. The $97.33 average target is 173.94% above today’s ($35.53) stock price. Ophthotech Corporation has been the topic of 14 analyst reports since August 4, 2015 according to StockzIntelligence Inc. As per Thursday, September 3, the company rating was initiated by Citigroup. The stock of Ophthotech Corp (NASDAQ:OPHT) earned “Buy” rating by Chardan Capital Markets on Monday, December 14. As per Thursday, August 4, the company rating was maintained by Citigroup. JP Morgan upgraded Ophthotech Corp (NASDAQ:OPHT) rating on Thursday, June 2. JP Morgan has “Overweight” rating and $84 price target. Stifel Nicolaus maintained the shares of OPHT in a report on Thursday, August 6 with “Buy” rating. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Sell” rating given on Friday, August 7 by Goldman Sachs. Oppenheimer reinitiated Ophthotech Corp (NASDAQ:OPHT) rating on Friday, August 14. Oppenheimer has “Outperform” rating and $95.0 price target. Chardan Capital Markets maintained the shares of OPHT in a report on Tuesday, August 4 with “Buy” rating. On Friday, January 8 the stock rating was initiated by Suntrust Robinson with “Buy”. On Wednesday, April 27 the stock rating was initiated by Barclays Capital with “Overweight”.
According to Zacks Investment Research, “Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1.95 in 2016 Q2. Its up 0.45, from 1.5 in 2016Q1. The ratio improved, as 21 funds sold all Ophthotech Corp shares owned while 34 reduced positions. 38 funds bought stakes while 69 increased positions. They now own 41.31 million shares or 29.52% more from 31.90 million shares in 2016Q1.
Great West Life Assurance Can holds 0% or 2,200 shares in its portfolio. Credit Suisse Ag holds 0% of its portfolio in Ophthotech Corp (NASDAQ:OPHT) for 31,432 shares. The Iowa-based Principal Fincl Group Inc has invested 0% in Ophthotech Corp (NASDAQ:OPHT). Geode Limited last reported 224,462 shares in the company. Peak6 Investments Lp last reported 5,716 shares in the company. Ameriprise Financial holds 30,192 shares or 0% of its portfolio. Eaton Vance Management holds 0.04% of its portfolio in Ophthotech Corp (NASDAQ:OPHT) for 286,600 shares. Price T Rowe Associate Md has 0.02% invested in the company for 1.77M shares. D E Shaw And last reported 0% of its portfolio in the stock. Tiaa Cref Invest Mngmt Ltd Llc last reported 141,025 shares in the company. Metropolitan Life Ny, a New York-based fund reported 22,221 shares. Prudential Fincl holds 0% or 5,587 shares in its portfolio. The Massachusetts-based Opaleye Mngmt has invested 3.51% in Ophthotech Corp (NASDAQ:OPHT). Dai Ichi Life Ins Communications last reported 21,671 shares in the company. Senator Investment Gp L P holds 0.29% or 350,500 shares in its portfolio.
Insider Transactions: Since May 24, 2016, the stock had 1 insider buy, and 13 sales for $77.61 million net activity. PATEL SAMIR CHANDRAKANT sold $1.28M worth of stock. $978,899 worth of Ophthotech Corp (NASDAQ:OPHT) was sold by GUYER DAVID R on Monday, October 3. 671 shares with value of $38,381 were sold by SBLENDORIO GLENN on Wednesday, June 1. On Tuesday, May 24 the insider Novo A/S sold $63.70 million. Bolte Axel bought $199,395 worth of stock.
Ophthotech Corporation is a biopharmaceutical company. The company has a market cap of $1.28 billion. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration . It currently has negative earnings. The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
OPHT Company Profile
Ophthotech Corporation, incorporated on January 5, 2007, is a biopharmaceutical company. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV), a specific type of wet AMD. It is also investigating the potential of an ophthalmic formulation for tivozanib, a molecule VEGF tyrosine kinase inhibitor, for which the Company has an option for a license.
More notable recent Ophthotech Corp (NASDAQ:OPHT) news were published by: Streetinsider.com which released: “Ophthotech Corp (OPHT) Misses Q3 EPS by 7c” on November 08, 2016, also Streetinsider.com with their article: “Ophthotech Corp (OPHT) Announces Publication of Strong Fovista Phase 2b Data …” published on October 31, 2016, Fool.com published: “Why Ophthotech Corp. Plunged 42% in March” on April 07, 2016. More interesting news about Ophthotech Corp (NASDAQ:OPHT) were released by: Fool.com and their article: “Here’s Why Ophthotech Corporation Is Dropping Today” published on September 30, 2016 as well as Reuters.com‘s news article titled: “BRIEF-Ophthotech Corp & Ajinomoto Althea entered into a clinical and comme…” with publication date: November 04, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.